ReviewAnti-TNF therapy: Safety aspects of taking the risk
Introduction
The prognosis and well being of patients with rheumatoid arthritis (RA) have markedly improved over the last few decades due to prompt diagnosis, the systematic introduction of disease-modifying anti-rheumatic drugs (DMARDs) at an early stage of the disease, the use of DMARD combinations, and the availability of more effective anti-rheumatic agents [1], [2], [3], [4], [5], [6], [7].
The development of biologic agents during the last decade and in particular TNF alpha inhibitors (anti-TNF) represents a major breakthrough for the treatment of moderate to severe forms of RA. Until now, valid safety data has been obtained from the commercial randomized controlled trials (RCTs) and from post-marketing primarily national patient registries, which are based primarily on the three main anti-TNF drugs; infliximab, a chimeric (human/murine) IgG1 monoclonal antibody directed against TNF; adalimumab, a fully humanized IgG1 monoclonal antibody that inhibits TNF; and etanercept, a recombinant fusion protein that consists of the soluble TNF receptor (p75) linked to the Fc portion of human IgG1. However, there are growing efficacy and safety data regarding the two new commercially available agents certolizumab pegol (Cimzia, UCB) a human anti-TNF-alpha antibody Fab' fragment that is chemically linked to polyethylene glycol and golimumab, a human IgG1 kappa monoclonal antibody specific for human TNF-alpha that neutralizes TNF-alpha activity (Symponi, Centocor).
Similar to most active therapies, highly effective interventions raise concerns about adverse effects. Conflicting data have been published on increased rates of infections and malignancies associated with anti-TNF agents. The treatment response and remission and drug survival rates concerning this advancing mode of therapy are still under continuous investigation [8], [9].
This review focuses on recent publications that evaluate the association between anti-TNF therapy and infection, malignancy and drug survival rates, in order to assess the risks of this modern mode of therapy.
Section snippets
Infections
The issue of anti-TNF therapy and the possibility of associated risks for infections are in debate in the literature [10]. There is mounting evidence from RCTs as well as from observational cohort studies, that patients treated with anti-TNF agents are at increased risk of bacterial infections compared to patients treated with DMARDs, especially early in the course of treatment. Curtis et al. [8] showed that over a 20-month follow-up period , the multi-variable adjusted risk of hospitalization
Malignancy
The role of anti-TNF therapy n carcinogenesis and tumor progression is in dispute. The effect is incompletely understood, but it seems quite likely that this type of therapy affects different types of neoplasms at different time points during carcinogenesis [42], [43], [44], [45]. Interestingly, new data imply that anti-TNF may even serve as an adjunct to therapy for advanced cancer [44], [45]. Accordingly, the consequences of anti-TNF treatment on the short-term and long-term occurrences of
Drug survival
In clinical practice, drug-related side effects, primary non-response, or secondary drug resistance to anti-TNF agents are common problems [70], [71]. The risk of acute infusion reactions with infliximab varies considerably (between 0.8% and 8.8% per infusion) and affects approximately 10% to 23% of patients per year [72], [73], [74], [75], [76], [77], [78]. Cheifetz et al. [73], [74] distinguished acute infusion reactions occurring within 24 h and delayed infusion reactions occurring from 1 to
Take-home messages
- •
RCTs of selected RA patients suggest that TNF antagonists increase the risk of infection minimally, if at all.
- •
Patients receiving anti-TNF therapy may be more likely to be admitted to the hospital if they have an infection.
- •
Treatment with anti-TNF has been recognized as a risk factor for active TB.
- •
Most cases of TB develop soon after treatment initiation and correspond to reactivation of a latent TB infection.
- •
Significantly higher crude incidence rates of herpes zoster were demonstrated in patients
References (92)
- et al.
Predicting response to anti-TNF treatment in rheumatoid arthritis patients
Autoimmun Rev
(2009) - et al.
The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases
Autoimmun Rev
(2010) - et al.
DMARDS and infections in rheumatoid arthritis
Autoimmun Rev
(2008) - et al.
Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal
Autoimmun Rev
(2009) - et al.
Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry
Autoimmun Rev
(2010) - et al.
Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients
Autoimmun Rev
(2009) - et al.
Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis
Autoimmun Rev
(2010) - et al.
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
Lancet
(2004) Tumour necrosis factor antagonists: structure, function, and tuberculosis risks
Lancet Infect Dis
(2008)- et al.
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer
Ann Oncol
(2008)
Cancer after kidney transplantation in the United States
Am J Transplant
The incidence and management of infusion reactions to infliximab: a large center experience
Am J Gastroenterol
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Lancet
TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease
Joint Bone Spine
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists
Arthritis Rheum
Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies
Arthritis Rheum
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register
Arthritis Rheum
The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis
Curr Opin Rheumatol
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
Rheumatology (Oxford)
Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients
Rheumatology (Oxford)
Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation
Ann Rheum Dis
Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial
Arthritis Rheum
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial
Arthritis Rheum
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial
Arthritis Rheum
Infections associated with tumor necrosis factor-alpha antagonists
Medicine (Baltimore)
Treatment of latent tuberculosis infection
N Engl J Med
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
N Engl J Med
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)
J Rheumatol
Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis
J Rheumatol
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate
Arthritis Rheum
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden
Arthritis Rheum
Infections and anti-tumor necrosis factor alpha therapy
Arthritis Rheum
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report
Arthritis Rheum
Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers
J Rheumatol
Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy
Arthritis Rheum
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry
Arthritis Rheum
Close association of herpes zoster reactivation and systemic lupus erythematosus (SLE) diagnosis: case–control study of patients with SLE or noninflammatory nusculoskeletal disorders
J Rheumatol
Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders
Rheumatology (Oxford)
The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom
Arthritis Rheum
Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents
JAMA
Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice
Proc Natl Acad Sci U S A
Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures
J Virol
Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis
Gut
Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy
Ann Rheum Dis
Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C
J Rheumatol
Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection
Arthritis Rheum
Cited by (112)
Do immunosuppressive agents hamper the vaccination response in patients with rheumatic diseases? A review of the literature
2021, TherapiesCitation Excerpt :It has been well documented that patients with auto-immune disease are more susceptible to infection than similar populations without auto-immune disease [1,2]. This is due, on the one hand, to the immune system dysregulation and on the other hand, to the use of immunosuppressive [3–7], and especially biological agents [2,8,9]. Moreover, inflammatory symptoms of infection may be masked by some of these agents [10,11].
Tolerance and efficacy of anti-TNF currently used for severe non-infectious uveitis
2021, Autoimmunity ReviewsElevation of tumor necrosis factor alpha levels is associated with restless legs symptoms in clinically depressed patients
2018, Journal of Psychosomatic ResearchClitoria ternatea flower petals: Effect on TNFR1 neutralization via downregulation of synovial matrix metalloproteases
2018, Journal of EthnopharmacologyClinical significance of a novel uric-acid-based biomarker in the prediction of disease activity and response to infliximab therapy in Crohn’s disease
2023, Scandinavian Journal of Gastroenterology